Obesity Clinical Trial
Official title:
Interventions to Reduce Sedentary Behavior at Work: Pilot Study
NCT number | NCT03816150 |
Other study ID # | 25912 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 13, 2016 |
Est. completion date | November 30, 2020 |
Verified date | September 2021 |
Source | Medical College of Wisconsin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Prior research suggests that sedentary behavior is detrimental to health, independent of exercise activity. Sedentary behavior is defined as behaviors that involve low levels of energy expenditure ≤1.5 metabolic equivalents (including sitting, watching TV, reading, and driving). Due to the high burden of sedentary behaviors in modern-day societies, this has potential implications for novel intervention strategies to reduce sitting (outside of regular exercise activity) and improve health. In addition, the modern workplace fosters sedentary behavior, and sedentary jobs now make up more than 80% of the workforce. The goal of this project is to implement interventions to reduce sedentary behavior at work and evaluate their impact on physiologic parameters and markers of disease. Specifically, the investigators/study team will use direct measurement of vascular endothelial function as one of our outcomes. This is important since conduit artery endothelial function, assessed by arterial flow-mediated dilation (FMD), is a powerful indicator of vascular inflammation and predictor of future cardiovascular events.
Status | Completed |
Enrollment | 16 |
Est. completion date | November 30, 2020 |
Est. primary completion date | September 18, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Sedentary office workers the Medical College of Wisconsin who spend greater than 75% of their (8 hours or longer) work-day sitting at a desk. This includes at least 1 period of 2 hours or longer of uninterrupted sitting time per work day. - Body mass index of 26.0-44.9 - Willing and able to sign Informed consent - Permission from the subject's supervisor to participate in the intervention Exclusion Criteria: - Known history of atherosclerotic cardiovascular disease, including myocardial infarction, stroke, coronary stent, coronary artery bypass grafting, angina and peripheral vascular disease - Diabetics on insulin or other diabetic medications (pre-diabetes would be acceptable, defined as a HbgA1c of 5.7 to 6.4%, and not on medications) - Elevated blood pressure (SBP=150 mm Hg or DBP =90 mm Hg) or on medication for hypertension; or SBP < 100 mm Hg. - On cholesterol-lowering medication or LDL-C cholesterol =190 mg/dL - Pregnancy, lactating or planning to get pregnant within the next 6 months - Current tobacco use within previous 12 months. Tobacco use included cigarettes, cigars, and all forms of smokeless tobacco. - Current excessive alcohol use (defined as more than 14 drinks/week for women, more than 28 drinks/week for men) - Current illicit drug use, defined as overuse of prescription medications, or of any illegal mind altering substances. - Known thyroid disease - Taking diet pills, or supplements other than those contained in a multi-vitamin - History of musculoskeletal surgery/injury that would interfere with prolonged periods of standing - History of use of PDE-5 inhibitors for any reason within the last 5 days of screening visit, and the inability to hold use of PDE-5 inhibitors for 5 days prior to each of the FMD evaluations. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical College of Wisconsin |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The feasibility of implementing workplace interventions to reduce sedentary time, specifically using a sit-stand desk. We will survey the subjects regarding the feasibility and likability of the sit-stand workstation | Ten Questions using a Likert Scale. Each question has the same 5 options: strongly agree, agree, neutral, disagree, strongly disagree. | through study completion, an average of 6 months | |
Primary | The feasibility of implementing workplace interventions to reduce sedentary time, specifically using a sit-stand desk. We will survey the subjects regarding the feasibility and likability of the sit-stand workstation | Objectively quantify sitting, standing and walking times (sedentary vs. non-sedentary) using an accelerometer device that adheres to the subjects thigh | Change from baseline sedentary behaviors after 6 months | |
Secondary | The Impact of reducing sedentary time on physiological outcomes | Measure Flow Mediated Dilation (FMD) | Change from baseline after use of a standing desk, through study completion, an average of 6 months | |
Secondary | The Impact of reducing sedentary time on physiological outcomes | Measure Near-infrared spectroscopy is a spectroscopic (NIRS) | Change from baseline after use of a standing desk, through study completion, an average of 6 months | |
Secondary | The Impact of reducing sedentary time on physiological outcomes | anthropometrics: Change from baseline body mass index after use of a standing desk | Through study completion, an average of 6 months | |
Secondary | The Impact of reducing sedentary time on physiological outcomes | measure cardiac hemodynamics: Change from baseline systolic and diastolic blood pressure after use of a standing desk, | Through study completion, an average of 6 months | |
Secondary | The Impact of reducing sedentary time on physiological outcomes | measure cardiac hemodynamics: Change from heart rate after use of a standing desk, | Through study completion, an average of 6 months | |
Secondary | The Impact of reducing sedentary time on physiological outcomes | Measure blood lab results: Change from baseline fasting lipids, insulin resistance, hemoglobin A1c and C-reactive protein (CRP) | At baseline after use of a standing desk, through study completion, an average of 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |